Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivozanib - AVEO Oncology/Kyowa Kirin

Drug Profile

Tivozanib - AVEO Oncology/Kyowa Kirin

Alternative Names: ASP 4130; AV-951; AVE-951; FOTIVDA; Fotivda; Kil8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate

Latest Information Update: 25 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AstraZeneca; AVEO Oncology; Bristol-Myers Squibb; EUSA Pharma; Institute Gustave-Roussy; Kyowa Kirin; Northwestern University; Pharmstandard
  • Class Antineoplastics; Eye disorder therapies; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Liver cancer; Soft tissue sarcoma
  • Phase I/II Solid tumours
  • Preclinical Age-related macular degeneration
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 01 Oct 2021 Phase-I/II clinical trials in Solid tumours (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05000294)
  • 09 Sep 2021 Phase-III clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (PO) (NCT04987203)
  • 09 Sep 2021 Phase-III clinical trials in Renal cell carcinoma (Monotherapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in USA (PO) (NCT04987203)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top